Beta Galactosidase: What Are the New Trends and Shifts in the Global Market? What Measures Should Buyers Take to Seize Opportunities and Address Challenges Brought by Market Changes?

As a new type of foreign trade service provider driven by dual engines of technology transformation and export trading, HiSiaddi has built a service system defined as "1+2+3+4=1", which can supply original factory sources of Beta Galactosidase from multiple well-known brands.

Adopting the "1+1>2" business model, HiSiaddi focuses on the integrated development of technology transformation and export business. It consistently tracks the global Beta Galactosidase market from both scientific research and commercial perspectives. Today, we conduct a professional analysis of the latest shifts and trends across the global Beta Galactosidase industry.

If you require more comprehensive and valuable market intelligence on Beta Galactosidase, please contact HiSiaddi customer service.

I. Five Core New Trends in the Global Beta Galactosidase Market (Precise Data + Tangible Industry Shifts)

1. Demand Side: Surging Rigid Demand from Lactose Intolerance + Cross-Sector Application Expansion Fuel Rapid Market Growth

Over 65% of the global population suffers from lactose intolerance, with an apparent incidence rate exceeding 80% in the Asia-Pacific region and over 70% among Chinese adults. This directly propels the lactose-free dairy market to expand at an annual growth rate of 9.7%. The market size is projected to rise from USD 1.25 billion in 2023 to USD 2.18 billion by 2030, representing a compound annual growth rate (CAGR) of 8.3%.

Key Shifts:

· Demand for traditional dairy products (milk, yogurt, cheese) remains steady, while portable functional beverages (ready-to-drink flavored milk, protein shakes) stand as the core growth driver. The global launch volume of new products in this segment surged 42% year-on-year from 2025 to 2026.

· Accelerated cross-industry penetration: Beta Galactosidase has expanded beyond dairy into infant formula (new national standards mandate lactose accounts for ≥90% of carbohydrates), special medical food, sports nutrition supplements, premium pet food and biomedical intermediates. The share of non-dairy applications is expected to climb from 18% in 2022 to 35% by 2026.

2. Technology Side: Synthetic Biology & Immobilized Enzyme Technology Breakthroughs Drive Dual Benefits of Cost Reduction and Performance Upgrade

Technological innovation acts as the core industry growth driver. Genetically engineered strains and third-generation immobilized enzyme technology have become mainstream commercial solutions. After the full commercialization of immobilized enzyme technology in 2026, production costs will drop by 23%, while enzyme activity stability will rise above 6,000 IU/g.

Key Shifts:

· Upgraded enzyme performance: High temperature resistance, acid & alkali tolerance and high activity have become standard features. New-generation Beta Galactosidase can hydrolyze lactose to below 0.1 g/L within 72 hours under low-temperature conditions, catering to low-temperature dairy processing scenarios.

· Diversified formulations: Liquid Beta Galactosidase still dominates the market with a 48.4% share, yet powder, granular and microcapsule variants witness explosive growth. Microcapsule types enable slow release, suitable for solid beverages and baked goods.

· Clean label development: Non-GMO, additive-free and naturally sourced raw materials have become key R&D priorities. Over 45% of all new Beta Galactosidase products launched globally in 2026 highlight clean label concepts, aligning with stringent food additive regulations in the EU and North America.

3. Supply Side: Rising Chinese Production Capacity & Accelerated Import Substitution Restructure Competitive Landscape

Global Beta Galactosidase production capacity is concentrated in North America, Europe and China. Domestic Chinese manufacturers (such as VTR Bio and Vland Biotech) have achieved a 92% import substitution rate in mid-to-low-end markets, while several enterprises have made breakthroughs in high-end segments. China’s global production capacity share jumped from 22% in 2020 to 38% in 2024.

Key Shifts:

· International giants (Novonesis, Kerry): Focus on high-end technology, brand assets and integrated solutions. Enzyme formulation + application solution services account for 28% of their revenue, targeting high value-added markets.

· Domestic Chinese manufacturers: Leverage cost advantages and capacity expansion while developing differentiated formulations to resolve the production-consumption mismatch of "northern production, southern sales". The enzyme activity stability and batch consistency of selected domestic players have reached international standards, with prices 30%-40% lower than imported equivalents.

· Intensified industry consolidation: Global M&A cases rose 25% year-on-year between 2023 and 2025. Leading enterprises consolidate production capacity and technologies via acquisitions, while small-scale low-efficiency production lines are phased out.

4. Regional Side: Asia-Pacific Emerges as Core Growth Market; High-End Orientation in Europe & North America vs Mass Popularization in Asia-Pacific Form Distinct Segmentation

North America and Europe hold a combined 45% global market share thanks to mature regulatory frameworks, while the Asia-Pacific region boasts the fastest growth rate, with its market share projected to reach 32% by 2030, led by China and India.

Key Shifts:

· European & North American markets: Dominated by high-end, refined products. Lactose-free dairy goods carry a 20%-30% price premium. Buyers prioritize non-GMO certification, organic certification and full batch traceability, with customized requirements (specific enzyme activity, targeted hydrolysis degree) exceeding 50% of total orders.

· Asia-Pacific markets: Centered on mass-market affordability. China’s per capita dairy consumption hit 42 kg in 2025, with market penetration rising rapidly in third- and fourth-tier cities and county-level regions. Buyers prioritize cost control, stable production capacity and basic regulatory compliance.

· Emerging markets (Southeast Asia, Latin America): Demand remains in the nascent stage, dominated by low-cost general-grade Beta Galactosidase with loose compliance requirements. These regions serve as primary export destinations for China’s mid-to-low-end production capacity.

5. Policy Side: Tightening Global Regulation Raises Compliance Barriers

The EU revised its food enzyme regulation (Regulation EU 2023/463) in 2023, imposing stricter controls over enzyme sources, production workflows and residual limits. China updated the National Food Safety Standard for Food Additive Usage in 2024, clarifying permitted application scope, enzyme activity labeling specifications and heavy metal residue limits for Beta Galactosidase.

Key Shifts:

· Mandatory compliance documentation: ISO 22000, FSSC 22000, Kosher and Halal certifications have become mandatory entry requirements for cross-border procurement, with over 70% of international buyers listing compliance certificates as access thresholds.

· Standardized labeling: Enzyme activity units (ALU/g), strain origin, production batch numbers and shelf life must be clearly marked; false labeling of enzyme activity is prohibited, with violating enterprises facing heavy fines and market bans.

· Improved traceability systems: European and North American markets mandate full value chain traceability, requiring complete records for every stage from strain cultivation, fermentation and purification to finished product delivery, forcing suppliers to upgrade quality control systems.

II. Core Challenges & Opportunities for Downstream B2B Buyers by Category

1. Large-Scale Dairy Processing Enterprises (Annual Procurement ≥ 50 tons, e.g., Danone, Yili)

Core Challenges

· Cost pressure: High-end Beta Galactosidase accounts for 8%-15% of total processing costs, compounded by a 23% year-on-year price surge in raw whey powder in 2024, squeezing profit margins.

· Technical adaptation barriers: Existing production lines are calibrated for traditional Beta Galactosidase; retrofitting to accommodate new heat-resistant, acid & alkali-tolerant variants incurs high costs and long lead times.

· Elevated compliance risks: Multinational production layouts require simultaneous adherence to EU, North American and Chinese standards, driving up compliance audit costs and administrative complexity.

Core Opportunities

· High-end product price premiums: Launch premium lactose-free dairy and special medical food lines to capture a 20%-30% margin premium, offsetting raw material cost pressures.

· Supply chain integration advantages: Large procurement volumes enable long-term framework agreements with leading suppliers to lock in favorable pricing and stable capacity, with priority access to customized technical support.

· Cross-industry expansion potential: Leverage Beta Galactosidase technology to branch into sports nutrition and pet food, unlocking new revenue streams.

2. Medium & Small-Scale Dairy Enterprises (Annual Procurement 10–50 tons, regional dairies, specialty milk producers)

Core Challenges

· Weak bargaining power: Small order volumes prevent access to bulk pricing, resulting in production costs 10%-20% higher than large competitors.

· Unstable supply chains: Small-tier suppliers face capacity constraints, risking production disruptions and inconsistent batch quality.

· Insufficient innovation capacity: Limited capital and technical resources delay adoption of advanced Beta Galactosidase variants and application technologies, leading to homogeneous products and weak competitiveness.

Core Opportunities

· Niche market breakthrough: Focus on regional specialty and niche segments (organic lactose-free yogurt, children’s lactose-free milk) to avoid cutthroat competition with industry giants and build differentiated advantages.

· China’s domestic capacity dividend: Partner with high-quality local Chinese suppliers for superior cost performance; many manufacturers provide free sample testing and technical guidance to reduce trial-and-error expenses.

· Agile operational flexibility: Short decision-making chains enable rapid response to market shifts and quick product portfolio switches (e.g., shifting from dairy milk to lactose-free plant-based milk).

3. Dietary Supplement & Functional Food Manufacturers (Annual Procurement 5–20 tons)

Core Challenges

· Formulation compatibility issues: Beta Galactosidase interacts with other ingredients (probiotics, vitamins, plant extracts), often triggering activity conflicts and poor shelf stability.

· Intensified clean label pressure: End consumers demand "natural, additive-free" formulations; traditional chemically synthesized Beta Galactosidase loses market appeal, while naturally sourced alternatives carry steep price tags.

· Fierce market competition: Low industry entry barriers lead to severe product homogenization and price wars, compressing profit margins.

Core Opportunities

· Rapid demand growth: Global digestive health dietary supplements grow at over 15% annually, with online sales of Beta Galactosidase supplements rising 37.8% year-on-year.

· Differentiated composite formulations: Develop blended formulas combining Beta Galactosidase, probiotics and dietary fiber to boost product added value, delivering a 30%-50% price premium.

· Cross-border e-commerce dividends: Reach global consumers via Amazon, independent brand websites and other channels, bypassing intense offline retail competition.

4. Special Medical Food & Infant Formula Manufacturers (Annual Procurement ≥ 10 tons, high-purity requirements)

Core Challenges

· Stringent quality standards: Products demand ultra-high purity, high activity, zero impurities and allergen-free formulations with stable enzyme activity above 10,000 IU/g; extensive testing results in low qualification rates.

· Difficult supplier screening: Few qualified suppliers meet regulatory benchmarks; international giants charge premium prices, while domestic manufacturers display uneven technical capabilities, extending lengthy, costly screening cycles.

· Strict policy supervision: Special medical food and infant formula fall under high-priority regulatory oversight; formula or raw material replacements require lengthy re-approval processes with substantial compliance risks.

Core Opportunities

· Stable rigid demand: The global infant formula and special medical food market exceeds USD 100 billion, with lactose-free and low-allergy variants representing non-cyclical, steady demand.

· High value-added returns: Special medical food and infant formula carry extreme price premiums; Beta Galactosidase procurement accounts for a minimal share of total costs, yielding wide profit margins.

· Long-term partnership stickiness: Supplier contracts average 2.8 years once finalized, securing stable priority production capacity and resilient supply chains.

5. Feed & Pet Food Manufacturers (Annual Procurement 5–30 tons, mid-to-low-end requirements)

Core Challenges

· Extreme cost sensitivity: Thin profit margins in feed and pet food production mandate strict cost control for Beta Galactosidase, creating a risk of compromising quality for low pricing.

· Rigorous product stability requirements: Feed production involves high-temperature extrusion processing, which deactivates standard Beta Galactosidase and undermines product efficacy.

· Low market awareness: Livestock farmers and pet food brands lack understanding of Beta Galactosidase’s functional benefits, hindering market promotion.

Core Opportunities

· Massive untapped market potential: Premium pet food and young livestock feed segments grow rapidly; lactose-free formulations improve digestive efficiency and reduce diarrhea, with low market penetration and ample room for expansion.

· Well-matched domestic Chinese production capacity: Domestic manufacturers offer cost-effective mid-to-low-end Beta Galactosidase with mature heat-resistant variants tailored to feed and pet food applications.

· Differentiated competitive edge: Feed and pet food products fortified with Beta Galactosidase can market "easy digestion, low sensitivity" as core selling points to stand out from competitors.

III. Targeted Competitiveness Enhancement Strategies for Downstream B2B Buyers (Actionable Solutions by Enterprise Type)

1. Large-Scale Dairy Enterprises: Technical Upgrading + Supply Chain Price Lock-In + High-End Market Deep Cultivation

(1) Technical Upgrading: Adapt to New-Generation Beta Galactosidase to Cut Long-Term Costs

· Allocate 3%-5% of annual revenue to production line retrofits compatible with heat-resistant immobilized Beta Galactosidase, reducing per-unit enzyme consumption by 20% and boosting production efficiency by 30% post-upgrade.

· Collaborate with suppliers to develop customized Beta Galactosidase variants calibrated for distinct products (low-temperature yogurt, ambient milk) with tailored enzyme activity and hydrolysis levels to enhance finished product stability.

(2) Supply Chain Price Lock-In: Sign Long-Term Agreements to Hedge Price Volatility

· Establish 3–5 year long-term procurement contracts with 2–3 leading suppliers (a mix of international giants and top-tier domestic Chinese manufacturers) to lock in fixed pricing and production capacity, with contractual clauses for compensation for substandard batches.

· Build raw material inventory reserves of whey powder and other key inputs covering 3–6 months of production to mitigate price spikes.

(3) Deep Cultivation of High-End Markets: Launch High Value-Added Products to Capture Premium Margins

· Roll out premium lactose-free organic milk, low-allergy infant formula and functional yogurt, highlighting clean label, non-GMO and high digestibility selling points to command a 20%-30% price premium.

· Leverage established brand recognition to expand into mid-to-high-end markets in Southeast Asia and Latin America, avoiding saturated European and North American markets.

2. Medium & Small-Scale Dairy Enterprises: Differentiated Positioning + Domestic Supply Chains + Lightweight Innovation

(1) Differentiated Positioning: Focus on Niche Segments to Avoid Head-On Competition with Industry Leaders

· Exit mass-market product lines and specialize in regional niche offerings such as organic lactose-free yogurt and lactose-free children’s cheese to build small, specialized brand reputations.

· Market the unique selling proposition of "local milk sources + additive-free Beta Galactosidase" to align with regional consumer health preferences and cultivate word-of-mouth traction.

(2) Domestic Supply Chain Collaboration: Source from Chinese Manufacturers to Lower Costs & Stabilize Supply

· Screen 2–3 mid-to-high-end domestic Chinese suppliers with enzyme activity ≥5,000 ALU/g and ISO 22000 certification, delivering 30%-40% cost savings versus imported alternatives with equivalent quality standards.

· Negotiate small-batch, multi-delivery schedules with suppliers to flexibly match production output and minimize excess inventory.

(3) Lightweight Innovation: Low-Cost Rapid Product Iteration to Match Market Demand

· Retain standard liquid general-grade Beta Galactosidase compatible with existing production lines to eliminate costly factory retrofits.

· Launch 1–2 new product variants quarterly (e.g., lactose-free fruit milk, probiotic-infused lactose-free yogurt) to quickly respond to consumer trends and boost repeat purchase rates.

3. Dietary Supplement & Functional Food Manufacturers: Formulation Innovation + Clean Label Compliance + Cross-Border Channel Development

(1) Formulation Innovation: Develop Blended Formulas to Boost Added Value

· Launch core composite formulations combining Beta Galactosidase, probiotics and dietary fiber to strengthen gut health functionality, achieving a 30%-50% price premium.

· Customize targeted formulations for distinct consumer groups (elderly, children, fitness enthusiasts) to precisely match segmented demand.

(2) Clean Label Compliance: Source Naturally Derived Beta Galactosidase to Align with Consumer Trends

· Prioritize non-GMO, additive-free fungal-source Beta Galactosidase, labeled as "naturally extracted, mild and efficient" to build consumer trust.

· Secure organic and vegetarian certifications to unlock high-end consumer market segments.

(3) Cross-Border Channel Expansion: Deploy Online E-Commerce to Reach Global Consumers

· Establish storefronts on Amazon, Shopee and independent brand websites, marketing high-activity, lactose-free, easily absorbable product features to evade offline price competition.

· Deploy content marketing and live streaming campaigns to elevate brand visibility, raising online sales contribution to over 40% of total revenue.

4. Special Medical Food & Infant Formula Manufacturers: Rigorous Supplier Screening + Full-Link Quality Control + Compliance Prioritization

(1) Rigorous Supplier Screening: Establish Strict Entry Standards to Secure Premium Production Capacity

· Enforce stringent supplier qualification criteria: enzyme activity ≥10,000 IU/g, purity ≥99%, zero allergens, undetectable heavy metal residues and certified production capacity for special medical food-grade materials.

· Select one international industry leader and one high-end domestic Chinese manufacturer, signing exclusive long-term supply agreements to secure priority production capacity.

(2) Full-Link Quality Control: Strengthen Third-Party Testing to Ensure Regulatory Compliance

· Implement comprehensive testing protocols covering raw material intake, in-process production and finished product release, with full batch inspections for enzyme activity, purity, microbial content and heavy metals; reject all non-compliant batches.

· Partner with authoritative third-party testing bodies (SGS, Intertek) to generate official compliance reports satisfying global regulatory requirements.

(3) Proactive Compliance Management: Track Policy Updates & Preemptively Secure Global Certifications

· Assign dedicated teams to monitor regulatory revisions in the EU, North America and China, adjusting formulations and raw material sourcing in advance to prevent costly approval delays.

· Preemptively obtain Kosher, Halal, organic and non-GMO certifications to expand cross-border market access credentials.

5. Feed & Pet Food Manufacturers: Heat-Resistant Enzyme Selection + Cost Optimization + Selling Point Development

(1) Heat-Resistant Enzyme Selection: Adapt to Processing Conditions to Prevent Enzyme Activity Loss

· Prioritize heat-resistant Beta Galactosidase variants retaining over 30 minutes of viable activity at 90°C, compatible with high-temperature feed extrusion processes and securing ≥80% residual enzyme activity post-processing.

· Select granular and microencapsulated Beta Galactosidase to minimize activity loss during manufacturing and improve utilization efficiency.

(2) Cost Optimization: Streamline Procurement & Precision Dosing to Reduce Per-Unit Expenses

· Source bulk general-grade heat-resistant Beta Galactosidase from large-scale domestic Chinese manufacturers for 40%-50% cost savings versus imported equivalents.

· Calculate precise dosage levels based on raw material lactose content and processing parameters to eliminate over-dosing waste and cut per-unit enzyme costs.

(3) Differentiated Selling Point Development: Highlight Digestive Benefits to Boost Product Competitiveness

· Market feed products with core messaging: "Lactose-free, easy digestion, reduced diarrhea, accelerated growth" targeting young livestock and sensitive-gastrointestinal animals to increase farmer adoption.

· Position pet food lines as "low-allergy lactose-free, gut protection, reduced loose stool" to align with pet owners’ health priorities, delivering a 10%-20% product price premium.

If you require more authentic, objective profiles of major Chinese Beta Galactosidase brands, please contact HiSiaddi customer service.